BioSpace News Archive

CureVac N.V. (NASDAQ:CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the first quarter of 2023 and provided a business update.

AUM Biosciences Pte. Ltd. (“AUM”), a global clinical-stage biotechnology company focused on discovering and developing precision oncology therapeutics, announced today that the first patient has been dosed in its Phase 2 clinical trial evaluating AUM001 for the treatment of metastatic colorectal cancer (MSS CRC).

Day One Biopharmaceuticals announced management will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14 at 11:20 a.m. PT.

Sun Pharmaceutical Industries Limited and Philogen S.p.A announced that they have entered into a licensing agreement for commercializing Philogen’s specialty product, Nidlegy™ in the territories of Europe, Australia and New Zealand.

Spexis AG, a clinical-stage biopharmaceutical company focused on rare diseases and oncology, announced its financial results for the full year of 2022 and provided a strategic business update.

IRLAB Therapeutics AB announced that the company will present at ABGSC’s Life Science Summit on Wednesday, May 31, 2023, in Stockholm, Sweden.

MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory and infectious diseases, announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for MP1032 for the treatment of Duchenne muscular dystrophy.

PainTEQ announced that on May 24, 2023 , the Patent Trial and Appeal Board (PTAB) issued a final written decision in an inter partes review (IPR) proceeding directed to U.S. Patent No. 10,426,539 (539 Patent), handing PainTEQ a decisive victory.

Tessa Therapeutics Ltd. announced two presentations featuring clinical data from the company’s autologous CD30.CAR-T therapy TT11 and off-the-shelf CD30 CAR EBVST therapy will be featured at the 17th International Conference on Malignant Lymphoma taking place from June 13-17, 2023, at Lugano, Switzerland.

MindBio Therapeutics Corp. demonstrates how 1 million microdoses of LSD could potentially benefit tens of thousands of patients with Depression.